Natalie Gaines, MD
Urogynecology and Reconstructive Pelvic Surgery · Amarillo, TXNPI 1376855312
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,540 of the $7,325 with a category attached, or 89.3%. 35 manufacturers reported payments, led by Medtronic at 31.4% of the total. 2025 is the largest year on record at $1,967, 2.9 times the $690 reported in 2019.
Across 238 payments — averaging $30.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Cipla USA Inc.$1K
- Astellas Pharma US Inc$737
- Dendreon Pharmaceuticals LLC$341
- Coloplast$300
- AbbVie$251
- plus $2K from 29 others
What the payments were for
- Travel & lodging$78511%
- Food & beverage$6,54089%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 52 | $2,297 |
| Cipla USA Inc. | 1 | $1,302 |
| Astellas Pharma US Inc | 50 | $737 |
| Dendreon Pharmaceuticals LLC | 12 | $341 |
| Coloplast | 8 | $300 |
| AbbVie(2 entities) | 14 | $251 |
| Myriad Genetic Laboratories, Inc. | 7 | $242 |
| Sumitomo Pharma America, Inc. | 13 | $234 |
| Valencia Technologies Corporation | 8 | $178 |
| Johnson & Johnson | 10 | $172 |
| Pfizer | 9 | $161 |
| Urogen Pharma, Inc. | 8 | $143 |
| Intuitive Surgical | 1 | $97 |
| Axonics, Inc. | 2 | $97 |
| Urovant Sciences Inc | 6 | $90 |
| Teleflex LLC | 3 | $74 |
| Boston Scientific | 4 | $72 |
| Sun Pharmaceutical Industries Inc. | 3 | $70 |
| Merck | 3 | $61 |
| Tolmar Pharmaceuticals, Inc. | 4 | $52 |
| Novartis | 2 | $44 |
| Amgen | 2 | $41 |
| Olympus America Inc. | 2 | $40 |
| Blue Earth Diagnostics | 2 | $30 |
| Laborie Medical Technologies Corp. | 1 | $27 |
| Myovant Sciences Inc. | 2 | $25 |
| Integra Lifesciences Corporation | 1 | $23 |
| Accord Healthcare, Inc. | 1 | $20 |
| Coopersurgical, Inc. | 1 | $19 |
| Bayer | 1 | $16 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| 180 Medical, Inc. | 1 | $14 |
| Cycle Pharmaceuticals Inc | 1 | $14 |
| Antares Pharma, Inc. | 1 | $14 |
| Therapeuticsmd, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEMDRI (PLAZOMICIN)$1,302
- ALTAVIVA$705
- INTERSTIM$399
- Prolaris$155
- ALTIS$145
How this compares
$7,325 in reported general payments places this provider in the 60th percentile of 74 urogynecology and reconstructive pelvic surgery providers in Texas.
See all urogynecology and reconstructive pelvic surgery providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 462 | $279,545 |
| GemtesaVibegron | 172 | $94,419 |
| Mirabegron ErMirabegron | 63 | $37,573 |
| Estradiol | 396 | $25,463 |
| EstringEstradiol | 14 | $7,270 |
| Trospium Chloride ErTrospium Chloride | 27 | $4,467 |
| Trimethoprim | 54 | $4,123 |
| Oxybutynin Chloride ErOxybutynin Chloride | 165 | $2,694 |
| Desmopressin Acetate | 64 | $2,041 |
| Methenamine Hippurate | 38 | $2,000 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 110 | $1,616 |
| Tolterodine Tartrate ErTolterodine Tartrate | 13 | $1,303 |
| Gentamicin Sulfate | 19 | $981 |
| Clobetasol Propionate | 28 | $787 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 13 | $694 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $737 | $279,545462 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $234 | $94,419172 claims |
| PfizerEstring | $161 | $7,27014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 74 urogynecology and reconstructive pelvic surgery providers in Texas.
Other urogynecology and reconstructive pelvic surgery in Amarillo
- Stephen KrausSan Antonio$372K
- Keith XavierArlington$282K
- Tomas AntoniniAustin$183K
- Amanda WhiteAustin$108K
- Gazala SiddiquiHouston$81K
- Fiona LindoHouston$66K
- Peter LotzeHouston$48K
- Tracy Cannon-SmithArlington$29K
- Teresa IrwinSan Marcos$20K
- Oluwarotimi NetteyHouston$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.